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ABSTRACT   
BACKGROUND The contribution of behavioral changes to functional decline is yet to be 
explored in PPA. Objectives: (1) investigate functional changes in two PPA variants 
(semantic and non-fluent), at baseline and after 12 months; (2) investigate baseline 
differences in behavioral changes between groups, and (3) explore predictors of functional 
decline after a 12-month period.  
METHODS A longitudinal study involving 29 people with PPA (18 svPPA; 11 nfvPPA) 
seen annually in Sydney/Australia was conducted. 114 functional and behavioral assessments 
were included for within (repeated-measures ANOVA; annual rate of change; multiple 
regression analyses) and between group analyses (pair-wise comparisons).  
RESULTS Functional profiles in svPPA and nfvPPA were similar in people with up to 5 
years of disease duration. Behavioral changes were marked in svPPA patients (stereotypical 
behavior and apathy) but did not predict annual rate of change of functional abilities; global 
cognitive scores at baseline did. Despite mild behavioral changes in nfvPPA (disinhibition, 
apathy), these were significant predictors of annual rate of functional change.  
CONCLUSIONS The presentation and interplay of behavioral changes and functional 
disability differs in svPPA and nfvPPA. These varying factors should be taken into account 
when considering prognosis, disease management, and selection of outcome measures for 
interventions.   
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INTRODUCTION  
Primary progressive aphasia (PPA) refers to three primary clinical variants: semantic 
(svPPA), non-fluent (nfvPPA), and logopenic variant (lvPPA). SvPPA patients maintain 
fluent speech but have severe impairments in expressive and receptive single-word 
comprehension, which impair recognition of objects and people. In contrast, communication 
in nfvPPA involves effortful, halting speech with grammatical and speech production errors 
leading to non-fluent communication. LvPPA has a distinct pattern of speech disruption with 
overlaps with nfvPPA, however, in contrast to svPPA and nfvPPA is primarily pathologically 
associated with Alzheimer’s disease.[1-3]  
In PPA, assessment of language often outweighs assessment of functional disability. 
Functional deficits are defined as disability in activities of daily living (ADLs), comprising 
change in a number of daily tasks of varying levels of complexity.[4] Current diagnostic 
criteria for PPA states that ADLs are relatively well maintained during the initial phase of the 
condition.[1,5] Over time however, PPA becomes similar to all dementia syndromes, where 
localized language and cognitive dysfunction evolves into generalized dementia affecting 
multiple functional domains and leading to care facility placement.  
Recently, it has been described that decline in everyday function in LPA is initially 
limited to instrumental ADLs, in contrast to nfvPPA which shows more generalized decline 
across both basic and instrumental ADLs.[6] Similarly longitudinal functional changes may 
be more marked in nfvPPA than in svPPA, but the factors behind these are not well 
known.[7-10] While the relationship between behavioral symptoms and functional decline in 
LPA and nfvPPA has been compared, this relationship is yet to be understood in nfvPPA in 
comparison to svPPA, which is particularly intriguing in light of unremarkable behavioral 
changes in nfvPPA.  
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 This study aimed to (1) characterize functional deficits in svPPA and nfvPPA; (2) 
examine longitudinal functional deficits in relation to cognitive and behavioral symptoms; (3) 
identify predictors of functional disability in svPPA and nfvPPA over a 12-month period. 
 
METHODS 
Participants 
Twenty-nine participants (svPPA=18; nfvPPA=11) were consecutively recruited via 
convenience sampling from the FRONTIER Research Group in Sydney, and assessed either 
in the clinic, home or care facility on two separate occasions approximately one year apart  
(M=1.4y ± 0.6) between November-2007 and December-2011. A total of 114 functional and 
behavioral assessments were completed across the 29 participants over the study time period 
and included for the analyses. Participants were included at baseline if (1) they fulfilled 
current criteria for svPPA or nfvPPA;[1] (2) had a reliable proxy informant to report on 
everyday functioning and behavior (informants were judged reliable if they either lived with 
or regularly saw the patient, and if they were able to clearly articulate functional and 
behavioural information pertaining to the patient); (3) did not have any major physical 
impairment such as requiring mobility aids; (4) did not have major depressive symptoms as 
measured by the DASS-21 [11,12] and (5) had a longitudinal assessment within 18 months. 
People with a diagnosis of lvPPA were excluded from this study based on a combination of a 
neurological clinical assessment, neuropsychological data and in vivo β–amyloid imaging. Of 
note, in the nfvPPA group, 2/11 participants were later re-diagnosed with atypical 
Parkinsonian syndromes (Corticobasal Syndrome, CBS, or Progressive Supranuclear Palsy, 
PSP). Due to the already small participant numbers in this study, these participants were 
retained for the analyses. Finally, 7/11 from the nfvPPA subgroup, and 8/18 in the svPPA 
subgroup have died since this study was conducted.  
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A multidisciplinary consensus based on a neurological clinical assessment (JRH) and 
a comprehensive neuropsychological battery was used for the diagnosis. Estimated disease 
duration was calculated at time of diagnosis based on reported onset of symptoms by the 
informant.  
 
Instruments 
Functional assessment 
The Disability Assessment for Dementia (DAD) was used to assess level of 
functioning in activities of daily living (ADLs).[13] The DAD is an informant-based measure 
evaluating 23 instrumental activities of daily living (IADLs) and 17 to basic self-care 
(BADLs) and has been extensively used in frontotemporal dementia (FTD) studies.[7,9,14] 
IADL domains include: “meal preparation”, “telephoning”, “going on an outing”, “finance 
and correspondence”, “medications”, and “leisure and housework”; BADL domains evaluate 
“hygiene”, “dressing”, “continence”, and “eating”. Questions that are not applicable are 
excluded to avoid activity bias (e.g. finances; cooking). Total DAD score is reported as a 
percentage of remaining ability, where lower scores represent greater impairment. 
In order to further distinguish clinical differences between subgroups, total DAD, 
BADL and IADL sub-scores were included in the analysis. All caregivers were interviewed 
by experienced research occupational therapists (EM, COC or CK) at baseline and follow-up 
visits. 
 
Behavioral assessment   
The Cambridge Behavioral Inventory Revised (CBI-R) is a caregiver-based 
assessment that measures and discriminates behavior across ten domains.[15] For each of the 
45 items, the caregiver is required to rate behavioral changes on a four-point scale (0=never, 
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1=a few times per month, 2=a few times per week, 3=daily, and 4=constantly), where higher 
scores indicate higher frequency of abnormal behaviors.  
Given the FTD focus on this study, only four domains were included: ‘memory and 
orientation’, ‘abnormal behaviour/disinhibition’, ‘stereotypic and motor behaviors’ and 
‘apathy’.[16] Two people with svPPA did not have complete baseline and follow-up 
assessments.  
 
Brief cognitive assessment 
A brief screening tool sensitive to the early stages of dementia was used at baseline. 
The Addenbrooke’s Cognitive Examination Revised (ACE-R) assesses five cognitive 
domains: ‘attention and orientation’, ‘memory’, ‘verbal fluency’, ‘language’, and 
‘visuospatial’ abilities.[17] Total score is 100, where higher scores reflect greater cognitive 
ability. The 88/100 cut off yields 94% sensitivity and 89% specificity for diagnosing 
dementia, and the tool has been reported as useful in tracking PPA progression.[18]  
 
Data analyses 
Data were analyzed using the Statistical Package for Social Sciences 21.0 (SPSS). 
Participants were categorized according to length of symptoms at baseline. Two categories 
were created: ‘early stage’ referred to disease duration of less than five years; ‘moderate 
stage’ participants had five or more years of disease. The five-year cut-off was used in this 
sample for two reasons: firstly, all recruited svPPA patients [5], already had a disease 
duration longer than two years by the time they presented at the clinic for their baseline visit. 
Secondly, many patients from both the svPPA and nfvPPA subgroups were still managing a 
majority of their ADLs despite having at least 5 years of disease duration. Therefore a five-
year cut-off was deemed more suitable to represent ‘moderate stage’ for this study. The 
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baseline analyses (functional deficits and behavioral changes) focused on the early stage 
(svPPA, n=11/18; nfvPPA, n=11/11). The longitudinal analyses and the linear regression 
analysis included all participants. Of note, all moderate stage participants belonged to the 
svPPA group.  
Demographic data were analyzed using parametric independent samples t tests. 
Kolmokorov-Smirnov tests were used to determine normality of distribution of main 
variables of interest at baseline, and non-parametric measures were used to take into account 
the skewness of the data distribution in some of these variables. Mann-Whitney U tests were 
performed to analyze dementia subgroup differences within the ‘early’ stages in regards to 
functional deficits and behavioral change. At follow-up, all variables of interest were 
normally distributed. Repeated-measures ANOVA were used to investigate effect of 
diagnosis and time on total DAD, IADLs and BADLs scores. For these longitudinal analyses 
diagnostic sub-groups were analyzed as a whole (svPPA=18/18; nfvPPA=11/11) for more 
appropriate statistical inferences.   
In order to investigate which baseline scores could predict annual rate of change in 
functional scores, a forced entry multiple regression using the Enter method was performed 
for both the svPPA and nfvPPA subgroups. A forward sequential regression approach was 
used to conserve power given the small sample size. Annual rate of change in function was 
calculated by subtracting the follow-up total DAD score from the baseline total DAD score 
for each participant. The annual rate of change was used as the dependent variable, with five 
baseline scores used as independent variables. The choice of these variables was largely 
based on the differences between diagnostic groups at baseline: ACE-R, CBI-R memory 
score; CBI-R stereotypical behavior score; CBI-R apathy score; DAD total score. A series of 
regressions were run using differing block variations of entering variables to estimate the best 
model for predicting the annual rate of change.  
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RESULTS 
Demographics 
There were no differences observed between svPPA and nfvPPA for age or total years 
of education at baseline (all p’s>.05; Table 1). Length of symptoms was significantly longer 
for svPPA (p<.0001), whereas ACE-R scores were higher for nfvPPA (p<.05). Notably, 3/18 
(16.7%) of svPPA patients had predominantly right-sided temporal atrophy, and 2/11 (18.2%) 
of nfvPPA patients had apraxia of speech. 
 
(Insert Table 1 about here) 
 
Functional status at baseline assessments (first visit to research institute) 
In the svPPA sub-group, 11/18 participants were in the ‘early stage’, as defined by up 
to 5 years of disease duration, whereas all participants with a diagnosis of nfvPPA were 
included in the ‘early stage’ category due to their shorter length of history (Table 1). 
Overall ADL function was similar between svPPA and nfvPPA, as shown by the 
DAD total score (Figure 1, Panel A). When these scores were broken down into more 
complex instrumental (Figure 1, Panel B) and basic ADLs (Figure 1, Panel C), the similarity 
between groups remained. Interestingly, the outlier participant (very low functional scores) 
from the nfvPPA group in each of these figures went on to later develop an atypical 
Parkinsonian syndrome (CBS) (Figure 1).  
 
(Insert figure 1 about here) 
  
Behavioral changes at baseline 
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In parallel to functional disability, we also explored behavioral differences between 
the two PPA groups according to the duration of their symptoms since disease onset, in order 
to understand their potential contribution to ADL dysfunction. Early in the disease (‘early 
stage’), svPPA scored significantly higher in memory impairment than nfvPPA (U=15, z=-
2.829, p<.005). Higher levels of stereotypical behavior (U=26.5, z=-2.035, p<.05), and 
apathy (U=20.5, z=-2.439, p<.05) were also found in svPPA. The differences between both 
groups was substantial across these two domains, with 60% of patients from the svPPA group 
showing marked deficits, compared with only 9% of patients from the nfvPPA group.  Lastly, 
there were no significant differences for disinhibition scores between the PPA groups, with 
both groups demonstrating mild-moderate degree of changes. Interestingly, patients with 
nfvPPA who went on to develop an atypical Parkinsonian syndrome (CBS or PSP) tended to 
demonstrate higher scores on behavioral dysfunction at baseline (Figure 2).  
 
(Insert figure 2 about here) 
 
Longitudinal functional decline  
On average, follow-up assessments were conducted one year apart (M=1.4y ± 0.6). 
Repeated-measures ANOVA revealed an effect of time for total DAD score, IADL and 
BADL scores for both svPPA and nfvPPA. Critically, there were no interactions between 
time and diagnoses on any of these three analyses, confirming that both diagnostic groups 
showed similar decline on these three scores at the follow-up visit (Figure 3, Panels A, B, C).   
 
(Insert figure 3 about here) 
 
What factors can predict functional scores at follow-up? 
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For svPPA, a model trend emerged from the multiple regression for annual rate of 
change in functional (DAD) scores (F(13)=3.71, p=.05) consisting of (i) total DAD score at 
baseline, and (ii) ACE-R score at baseline. This model explained 36.4% of the variance of the 
annual rate of change in functional scores (p<.05) (Table 2), with most of the variance 
(35.5%) explained by the ACE-R score at baseline.  
Other models in this regression, containing forward sequentially added scores for 
apathy, stereotypical behavior and memory deficits in separate blocks were not significant.  
 
(Insert Table 2 about here) 
 
For nfvPPA, a significant model to predict annual rate of change in functional scores 
emerged from the multiple regression consisting of (i) CBI apathy and CBI stereotypical 
behavior, and (ii) total DAD score at baseline. This model explained 67.8% of the variance of 
the annual rate of change in DAD scores (p<.01) (Table 3). In this model, apathy and 
stereotypical behaviors made a very small but significant contribution (2.3% variance), 
whereas 65.5% of the variance was explained by the functional score at baseline (Table 3). 
ANOVA confirmed the statistical significance of this model (F(7)=4.91, p<.05). The 
sequential addition of global cognitive scores or memory deficits did not change the model.  
Of note, everyday memory deficits did not factor as a significant predictor of annual 
rate of change in ADL for either svPPA or nfvPPA patients in any of the regression analyses. 
 
(Insert Table 3 about here) 
 
DISCUSSION 
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This study demonstrated that decline (over a 12-month period) in ADL function can 
be largely predicted by cognitive scores in svPPA, and a combination of behavioral and 
functional scores in nfvPPA. It also confirmed that both PPA subgroups maintain a mild 
degree of functional impairment in the initial 5 years of the disease, but present distinct 
profiles of behavioral changes. Patients with svPPA show marked stereotypical behavior and 
apathy, but these do not seem to strongly predict functional decline.    
Baseline global cognitive score was found to be the strongest predictor of functional 
decline at follow-up for svPPA patients. Predictors of functional decline in nfvPPA, however, 
comprised a different model: a combination of baseline functional level, apathy and 
stereotypical behavior. It is interesting that baseline total ADL score was a predictive factor 
of functional decline in nfvPPA but not in svPPA patients.  Possible reasons include 
differences in disease stage at baseline between the two groups, or the well described slower 
rate of disease progression in svPPA.[8,19] In fact different patterns of ADL decline have 
been described between nfvPPA and svPPA patient groups with matched disease duration.[7] 
Regardless of the reasons for the different predictors of functional decline for these groups, 
these dissimilar factors should be taken into account when planning intervention strategies. 
For instance, given baseline functional performance predicts functional decline in nfvPPA, 
addressing any functional limitations should be a focus of treatment when patients present at 
the clinic. For example, if a nfvPPA patient presents with impairments in initiating and 
planning their basic ADLs, a supportive intervention may include setting up the requirements 
for an activity and assisting the person to sequence through the steps of the activity with 
verbal prompting.  
Our finding that a combination of behavioral and functional scores are the best 
predictors for functional decline in the nfvPPA group diverges from the Alzheimer’s 
literature, where reports have identified cognitive and behavioral factors as the key predictors 
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of ADL decline.[20,21] A possible reason for this divergence is the use of different 
assessments in comparison to current published studies. Additionally, the discrepancy in 
factors predicting ADL decline in AD and FTD variants might be a reflection of dissimilar 
pathologies as well as differences in affected neuroanatomical areas. Indeed, our group of 
nfvPPA patients included 2/11 with apraxia of speech. It is possible that the inclusion of 
different forms of nfvPPA may have impacted on the results. Future studies should include a 
larger sample of nfvPPA patients to allow subtype analysis.  
The identification of variables that do not contribute to functional decline is also 
critical in understanding changes over time. Behavioral changes are often evident at 
presentation in patients with svPPA, resembling behavioral variant FTD, but these behavioral 
changes do not seem to be relevant in predicting functional decline in svPPA. While marked 
behavioral changes are present in svPPA, they seem to somehow allow for continued 
participation in activities, albeit in a very rigid manner, instead of hindering their 
performance.[22-24] While there was a trend for global cognition to contribute to around a 
third of the variance in functional decline, the remaining factors which contribute to 
functional decline in svPPA remain unclear. The lack of behavioral factors contributing to 
ADL decline in the present study is, however, in contrast with a recent longitudinal study, 
which reported that increasing levels of apathy were correlated with declining ADL function 
in svPPA.[24] This is likely to be explained by the differences in methodological approach, 
i.e., cross sectional and longitudinal. Another important consideration is the inclusion of 3/18 
patients who had predominantly right-sided temporal lobe atrophy. For patients in the earlier 
stages of disease this may have impacted on their clinical presentation, with right-sided 
patients exhibiting worse behavioural symptoms than patients with predominantly left-sided 
temporal lobe atrophy. With progression however, the clinical profile of these subtypes 
becomes similar as left-sided svPPA also exhibit behavioural symptoms.[25,26] 
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Paradoxically, semantic deficits appear not to be a main contributing factor to functional 
decline, given that they appear very early in the disease and at a time when ADL function is 
very well preserved. The investigation of other factors affecting function in svPPA deserves 
future studies. 
The differences in behavioral changes in svPPA and nfvPPA are noteworthy and raise 
two critical points.[27-32] Firstly, people with svPPA have marked behavioral dysfunction, 
which at present, is overshadowed by the emphasis on the semantic deficits that characterize 
the syndrome. These marked behavioral changes are not part of the current diagnostic criteria 
but in many instances are of greater concern and distress to families than the well-reported 
semantic deficits.[33] Secondly, people with nfvPPA also demonstrate mild-moderate 
degrees of behavioral changes, such as apathy, which are equally underreported.[30,34] A 
proportion of the nfvPPA group with behavioral changes in the present study later developed 
an atypical Parkinsonian syndrome (CBS or PSP) as a secondary condition.[35-37] Although 
less severe than in svPPA, the behavioral changes observed in nfvPPA should be closely 
monitored for better disease management and prognosis. Interestingly, a recent paper 
reported no differences in levels of apathy between svPPA and nfvPPA groups.[38] This is 
likely to be explained by the use of different assessment tools; the CBI-R has been shown to 
be highly sensitive to behavioral changes in the FTD spectrum.[39] 
The present study also confirmed that functional abilities remain virtually intact for 
most PPA patients up to 5 years from disease onset, while behavioral changes are present 
from an early stage, most notably in svPPA. These findings reinforce the notion that 
assessment and monitoring of deficits in PPA should include a combination of tools 
measuring functional, behavioral, and cognitive deficits for a global and accurate 
characterization of impairments in PPA and care management.[40,41]  
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The nfvPPA group had circumscribed length of symptoms, which impeded a 
comparative analysis between both PPA groups in the later stages of the disease (those with 
longer history of symptoms). It is possible that the results of this study may have been 
different if the nfvPPA group had a 5-year disease duration similar to the svPPA group. In 
fact, a study comparing the rate of functional decline between FTD variants found that 
nfvPPA patients who had an average disease duration of 5 years declined faster than a svPPA 
group with a similar disease duration.[7] Future studies should investigate predictors of 
functional decline in PPA subgroups with matched disease durations. Nonetheless, this 
shorter disease duration is of clinical relevance in itself, and a number of reasons could 
explain this difference in PPA group composition. The most plausible reason is that nfvPPA 
leads to a more aggressive disease progression,[8] and are not referred to research centers 
later in the disease course. This pattern of shorter time from disease onset to presentation for 
assessment in nfvPPA has been previously reported.[35,42] Further, it is possible that in the 
earlier stages of disease the non-fluent language impairments are more obviously disruptive 
than the anomia seen in svPPA, so patients with nfvPPA are brought in for diagnosis sooner. 
Alternatively, by the time people with nfvPPA have a longer disease history (beyond 5 
years), they might have developed additional symptoms that lead to a revised diagnosis of 
atypical Parkinsonian syndrome (CBS or PSP).[43] Indeed, this occurred in a proportion 
(18%) of nfvPPA patients in this study.  
Some limitations in this study include the relatively small sample size,[44] which was 
related to the need to restrict to participants who had complete data at the follow-up visits. 
Still, this sample size is in line with other published longitudinal studies in PPA. Another 
potential limitation is the use of proxy reporting measures to assess ADL function and 
behavioral symptoms, which may increase the likelihood of response bias in the data.[45,46] 
Assessment by proxy, however, is the most common approach used in dementia studies.  
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In summary, this study demonstrated that functional profiles in svPPA and nfvPPA 
are rather similar in people with up to 5 years of disease duration. Behavioral changes are 
very marked in svPPA but do not predict annual rate of change in disability; instead, global 
cognitive scores at baseline do. Despite the less marked nature of behavioral changes in 
nfvPPA, they make a significant contribution to functional disability, with functional scores 
at baseline making the strongest contribution to functional decline in nfvPPA. The dissimilar 
factors behind functional decline in PPA should be taken into account when considering 
prognosis, referring to specialist community services and in designing well-targeted 
interventions.   
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Table 1. Comparison of age, gender, education, disease duration and ACE-R scores 
across nfvPPA and svPPA participants at baseline. Means; standard deviation (SD) in 
parentheses. 
 
 
svPPA 
(n = 18) 
nfvPPA 
(n = 11) 
p values 
Age years 65.3 (8.4) 66.6 (11.4)  .726₫ 
Gender (M/F) 12/6 9/2 .376† 
Education years 12.1 (3.6) 13.3 (4.3)  .426₫ 
Disease duration  5.1 (2.2) 2.6 (1) < 0.001₫ 
Baseline ACE-R score  56.8 (15.6) 71.7 (16.9) < 0.05₫ 
Abbreviations: svPPA=semantic variant primary progressive aphasia; nfvPPA=non-fluent 
variant primary progressive aphasia; ACE-R=Addenbrooke’s Cognitive Examination-
Revised; ₫t tests; †Chi square test 
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Table 2. Multiple regression model of annual rate of change in total DAD in people with 
svPPA (n=16)  
Independent 
Variable 
Unstandardized 
Beta coefficient 
Std. 
Error t Sig. R2 
F change 
in R2 
(Constant) -33.013 19.962 -1.654 .122 N/A N/A 
DAD Total -.366 .241 -1.523 .152 .009 .120 
ACER .839 .312 2.693 .018 .364 7.251* 
*p<.05  
DAD = Disability Assessment for Dementia; ACER = Addenbrooke’s Cognitive 
Examination Revised 
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Table 3. Multiple regression model of annual rate of change in total DAD for people 
with nfvPPA (n=11)  
Independent 
Variable 
Unstandardized 
Beta coefficient 
Std. 
Error t Sig. R2 
F change 
in R2 
(Constant) -127.280 29.313 -4.342 .003 N/A N/A 
CBI Apathy .738 .268 2.752 .028 
.023 .095 
CBI 
Stereotypical 
-.706 .250 -2.823 .026 
DAD Total 1.206 .320 3.770 .007 .678 14.215* 
* p<.01 
DAD = Disability Assessment for Dementia; CBI = Cambridge Behavioral Inventory 
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FIGURE LEGENDS 
 
Figure 1:  
Title: Comparison of baseline DAD functional scores across svPPA and nfvPPA 
 
Legend: Baseline comparisons of functional disability across ‘early stage’ svPPA (11/18) 
and nfvPPA (11/11) participants using Mann-Whitney U tests. (A) baseline total DAD 
scores; (B) baseline IADL scores; (C) baseline BADL scores. SvPPA=semantic variant 
primary progressive aphasia; nfvPPA=non-fluent variant primary progressive aphasia; 
DAD=Disability Assessment for Dementia; BADL=basic activities of daily living; 
IADL=instrumental activities of daily living. Circled points represent a patient who later 
went on to develop an atypical Parkinsonian syndrome (CBS or PSP). 
 
Figure 2:  
Title: Comparison of baseline CBI behavioral scores across svPPA and nfvPPA 
 
Legend: Baseline comparisons of behavioral changes across ‘early stage’ svPPA (11/18) and 
nfvPPA (11/11) participants using Mann-Whitney U tests. Scores of 50% or higher were 
considered to represent ‘marked behavioral changes’. SvPPA=semantic variant primary 
progressive aphasia; nfvPPA=non-fluent variant primary progressive aphasia; 
CBI=Cambridge Behavioral Inventory-Revised. Circled points represent a patient who later 
went on to develop an atypical Parkinsonian syndrome (CBS or PSP). 
 
Figure 3: 
Title: Comparison of longitudinal DAD functional scores across svPPA and nfvPPA 
 25 
 
 
Legend: Longitudinal comparisons (A, B, C) across both diagnostic subgroups as a whole 
(svPPA=18/18; nfvPPA=11/11) using repeated-measures ANOVA. (A) longitudinal change 
in total DAD scores; (B) longitudinal change in IADL scores (C) longitudinal change in 
BADL scores. SvPPA=semantic variant primary progressive aphasia; nfvPPA=non-fluent 
variant primary progressive aphasia; DAD=Disability Assessment for Dementia; 
BADL=basic activities of daily living; IADL=instrumental activities of daily living. 
 
 
 
 
